Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
Unresectable nodular and diffuse hepatocellular carcinoma (HCC) have a poor prognosis with limited treatment options. Systemic traditional chemotherapy has been only rarely reported, with unsatisfactory results. The aim of this prospective, non-randomized, non-blinded, single center clinical trial w...
Main Authors: | Laura Marconato, Silvia Sabattini, Giorgia Marisi, Federica Rossi, Vito Ferdinando Leone, Andrea Casadei-Gardini |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/5/1272 |
Similar Items
-
Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?
by: Do Young Kim
Published: (2017-06-01) -
A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function
by: Hyun Yang, et al.
Published: (2017-06-01) -
Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments
by: Hiroyuki Suzuki, et al.
Published: (2021-11-01) -
Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01) -
Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases
by: Giovanni Brandi, et al.
Published: (2018-06-01)